Abbonarsi

Tranexamic acid for gastrointestinal bleeding: A systematic review with meta-analysis of randomized clinical trials - 13/07/21

Doi : 10.1016/j.ajem.2020.08.062 
Po-Lin Lee, MD a, 1, Kai-Suan Yang, MD a, Hong-Wei Tsai, MD a, Sen-Kuang Hou, MD, PhD a, Yi-No Kang, MA a, b, c, d, , Chun-Chao Chang, MD e, f,
a Department of Emergency Medicine, Taipei Medical University Hospital, Taipei, Taiwan 
b Evidence-Based Medicine Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan 
c Research Center of Big Data and Meta-Analysis Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan 
d Institute of Health Policy & Management, College of Public Health, Taipei, Taiwan 
e Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan 
f Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Taipei Medical University, Taipei, Taiwan 

Corresponding authors.

Abstract

Background

Acute gastrointestinal bleeding is a common life-threatening emergent condition. Immediate tranexamic acid is useful for reducing hemorrhage following operation and bleeding trauma, but evidence on the effects of tranexamic acid in patients with gastrointestinal bleeding is limited or highly heterogeneous. It is still unclear about using tranexamic acid in the emergent condition of gastrointestinal bleeding. This study, therefore, aimed to determine whether or not tranexamic acid should be used in gastrointestinal bleeding management through systematic review and meta-analysis.

Methods

We searched three biomedical databases for relevant randomized controlled trials on this topic. Two authors independently selected studies and extracted data for bias assessment and meta-analysis of bleeding, further intervention, mortality, transfusion, and intensive care unit admission. Available data were pooled using a random-effects model, and the results were presented as risk ratios (RRs) with 95% confidence intervals (CIs). Heterogeneity and small study effects were also assessed.

Results

Thirteen randomized controlled trials (n = 2271) were included in the present synthesis. Our meta-analysis revealed that tranexamic acid significantly reduced the rates of continued bleeding (RR = 0.60; 95%CI, 0.43–0.84), urgent endoscopic intervention (RR = 0.35; 95%CI, 0.24–0.50), and mortality (RR = 0.60; 95%CI, 0.45–0.80) compared with the placebo.

Conclusion

According to the available evidence, the present synthesis confirms that tranexamic acid is an effective medication for patients with upper gastrointestinal bleeding. Early administration of tranexamic acid may be worth to be recommended for treating upper gastrointestinal bleeding in the emergency department. However, the effects of tranexamic acid on lower gastrointestinal bleeding warrant further clarification.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Gastrointestinal bleeding, Gastrointestinal hemorrhage, Tranexamic acid

Abbreviations : CI, RR, WMD


Mappa


© 2020  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 45

P. 269-279 - luglio 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Novel biomarkers of oxidative stress as predictive indicators of neurological outcome after out-of-hospital cardiopulmonary arrest
  • Kouhei Ishikawa, Yoshiaki Inoue, Yuka Sumi, Yutaka Kondo, Ken Okamoto, Hiroshi Tanaka
| Articolo seguente Articolo seguente
  • Checking the pulse in the 21st century: Interobserver reliability of carotid pulse detection by point-of-care ultrasound
  • David J. Smith, Robert Simard, Jordan Chenkin

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.